Northern Oak Wealth Management Inc. maintained its position in Thermo Fisher Scientific Inc (NYSE:TMO) during the first quarter, Holdings Channel reports. The institutional investor owned 3,412 shares of the medical research company’s stock at the end of the first quarter. Northern Oak Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $524,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. boosted its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer boosted its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the period. FNY Managed Accounts LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth approximately $153,000. Penserra Capital Management LLC boosted its position in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock worth $176,000 after buying an additional 100 shares during the period. Finally, Investment Centers of America Inc. purchased a new position in Thermo Fisher Scientific during the first quarter worth approximately $200,000. Institutional investors own 87.60% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.465% during mid-day trading on Monday, hitting $174.035. The stock had a trading volume of 382,936 shares. The company’s 50 day moving average price is $176.78 and its 200 day moving average price is $165.46. The stock has a market cap of $67.89 billion, a P/E ratio of 30.320 and a beta of 1.06. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.03 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/northern-oak-wealth-management-inc-has-524000-stake-in-thermo-fisher-scientific-inc-nysetmo/1487272.html.

TMO has been the topic of a number of research reports. Deutsche Bank AG upped their price target on Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. BTIG Research upped their price target on Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Barclays PLC set a $175.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 26th. Leerink Swann set a $187.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, April 27th. Finally, Bank of America Corporation upped their price target on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $188.56.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now owns 37,790 shares in the company, valued at approximately $6,660,865.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the transaction, the chief executive officer now owns 269,279 shares in the company, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. Insiders sold a total of 27,188 shares of company stock worth $4,702,223 in the last quarter. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.